# UNICANCER

Source: https://onco.cc/companies/unicancer/  
OnCo record `unicancer` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

UNICANCER is the network of France's comprehensive cancer centres and its academic trials sponsor.

## Summary

UNICANCER, based in Paris, is the network of France's comprehensive cancer centres and its academic trials sponsor, federating eighteen centres including Gustave Roussy, Institut Curie, the Institut du Cancer de Montpellier and Centre Jean Perrin. It runs the UCBG breast group, the PRODIGE gastrointestinal group whose PRODIGE 7 trial tested HIPEC, the GETUG genitourinary group and the ESME real-world database, with Christophe Le Tourneau, Jean-Yves Blay and Thomas Bachelot among the people linked. OnCo connects it to colorectal and triple-negative breast cancer, to real-world evidence, and to ideas such as a publicly held library of investigational drugs for academic combination trials and one standing umbrella trial for all rare cancers in a country. Slow enrolment is the bottleneck it exists to solve. Its PRODIGE, UCBG and ESME programmes are listed in the notes.

## Fields

- Kind: Company
- Last checked: 2026-09-06
- Also known as: Unicancer; Fédération Nationale des Centres de Lutte Contre le Cancer; FNCLCC
- Tags: cooperative-group
- HQ: Paris
- Type: cooperative-group
- Website: https://www.unicancer.fr

## Notes

- PRODIGE GI trials
- UCBG breast trials
- ESME real-world data

## Sources

- Official website: https://www.unicancer.fr
- UNICANCER: the centres: https://www.unicancer.fr/en/the-centres/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [HIPEC / PIPAC (intraperitoneal chemotherapy)](https://onco.cc/technologies/hipec/)
- institutions: [Centre Antoine Lacassagne](https://onco.cc/institutions/centre-antoine-lacassagne/), [Centre Eugène Marquis](https://onco.cc/institutions/centre-eugene-marquis/), [Centre François Baclesse](https://onco.cc/institutions/centre-francois-baclesse/), [Centre Georges-François Leclerc](https://onco.cc/institutions/centre-georges-francois-leclerc/), [Centre Henri Becquerel](https://onco.cc/institutions/centre-henri-becquerel/), [Centre Jean Perrin](https://onco.cc/institutions/centre-jean-perrin/), [Centre Léon Bérard](https://onco.cc/institutions/centre-leon-berard/), [Centre Oscar Lambret](https://onco.cc/institutions/centre-oscar-lambret/), [Fondation ARC pour la recherche sur le cancer](https://onco.cc/institutions/fondation-arc/), [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/), [Haute Autorité de Santé](https://onco.cc/institutions/has-france/), [Institut Bergonié](https://onco.cc/institutions/institut-bergonie/), [Institut Curie](https://onco.cc/institutions/institut-curie/), [Institut de Cancérologie de l'Ouest (ICO)](https://onco.cc/institutions/ico-angers-nantes/), [Institut de Cancérologie de Lorraine](https://onco.cc/institutions/institut-de-cancerologie-de-lorraine/), [Institut du Cancer de Montpellier (ICM)](https://onco.cc/institutions/icm-montpellier/), [Institut Godinot](https://onco.cc/institutions/institut-godinot/), [Institut National du Cancer](https://onco.cc/institutions/inca/), [Institut Paoli-Calmettes](https://onco.cc/institutions/institut-paoli-calmettes/), [Institut Strauss](https://onco.cc/institutions/institut-strauss/), [IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)](https://onco.cc/institutions/iuct-oncopole/), [Ligue nationale contre le cancer](https://onco.cc/institutions/ligue-contre-le-cancer/)
- terms: [Real-world evidence](https://onco.cc/terms/real-world-evidence/)
- trials: [GETUG 13](https://onco.cc/trials/getug-13/), [PEACE-1](https://onco.cc/trials/peace-1/), [PRODIGE 23](https://onco.cc/trials/prodige-23/), [PRODIGE 24 / CCTG PA6](https://onco.cc/trials/prodige-24/), [PRODIGE 4 / ACCORD 11](https://onco.cc/trials/prodige-4-accord-11/)
- people: [Anthony Gonçalves](https://onco.cc/people/anthony-goncalves/), [Christophe Le Tourneau](https://onco.cc/people/christophe-le-tourneau/), [Jean-Yves Blay](https://onco.cc/people/jean-yves-blay/), [Thomas Bachelot](https://onco.cc/people/thomas-bachelot/)
- key papers: [Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial](https://onco.cc/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- bottlenecks: [Trials enrol too few, too slowly](https://onco.cc/bottlenecks/b-trial-enrolment/)
- ideas: [A publicly held library of investigational drugs available for academic combination trials](https://onco.cc/ideas/idea-tr2-public-combination-formulary/), [One standing umbrella trial for all rare cancers in a country](https://onco.cc/ideas/idea-bio2-rare-cancer-umbrella-platform/)
- companies: [ARCAGY-GINECO](https://onco.cc/companies/arcagy-gineco/), [Intergroupe Francophone de Cancérologie Thoracique](https://onco.cc/companies/ifct/)

---
JSON: https://onco.cc/api/v1/entities/unicancer.json